Comparative Pharmacology
Head-to-head clinical analysis: AMLODIPINE MALEATE BENAZEPRIL HYDROCHLORIDE versus UNIVASC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMLODIPINE MALEATE BENAZEPRIL HYDROCHLORIDE versus UNIVASC.
AMLODIPINE MALEATE; BENAZEPRIL HYDROCHLORIDE vs UNIVASC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amlodipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance. Benazepril is an angiotensin-converting enzyme (ACE) inhibitor that prevents the conversion of angiotensin I to angiotensin II, resulting in vasodilation and reduced aldosterone secretion.
Angiotensin-converting enzyme (ACE) inhibitor; inhibits conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
Initial: 2.5-5 mg amlodipine / 10-20 mg benazepril orally once daily, titrated to 10/40 mg once daily based on response.
Initial: 7.5 mg orally once daily; titrate to 15-30 mg once daily. Maximum: 60 mg/day.
None Documented
None Documented
Amlodipine: 30-50 h (terminal), allowing once-daily dosing; benazeprilat: 10-11 h (terminal), effective for 24 h.
The terminal elimination half-life of moexiprilat, the active metabolite, is approximately 9.8 hours in patients with normal renal function. This supports once-daily dosing, though the antihypertensive effect may persist beyond 24 hours with continued therapy.
Renal: Amlodipine 10% unchanged, benazeprilat (active metabolite) 50-60% in urine; biliary/fecal: amlodipine 20-25% as metabolites, benazeprilat 10-20% in feces.
Univasc (moexipril) is primarily eliminated via renal excretion (approximately 50% of absorbed dose as unchanged drug and metabolites) and fecal excretion (about 50%).
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor